California State Teachers Retirement System cut its holdings in shares of Emergent Biosolutions Inc (NYSE:EBS) by 9.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 54,040 shares of the biopharmaceutical company’s stock after selling 5,334 shares during the period. California State Teachers Retirement System owned about 0.13% of Emergent Biosolutions worth $2,186,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Prudential Financial Inc. lifted its stake in Emergent Biosolutions by 3.6% during the third quarter. Prudential Financial Inc. now owns 75,378 shares of the biopharmaceutical company’s stock worth $3,049,000 after purchasing an additional 2,618 shares during the last quarter. New Amsterdam Partners LLC NY lifted its stake in Emergent Biosolutions by 66.3% during the third quarter. New Amsterdam Partners LLC NY now owns 163,337 shares of the biopharmaceutical company’s stock worth $6,607,000 after purchasing an additional 65,109 shares during the last quarter. Systematic Financial Management LP bought a new stake in Emergent Biosolutions during the third quarter worth $1,680,000. Macquarie Group Ltd. lifted its stake in Emergent Biosolutions by 60.1% during the third quarter. Macquarie Group Ltd. now owns 41,573 shares of the biopharmaceutical company’s stock worth $1,681,000 after purchasing an additional 15,604 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Emergent Biosolutions by 7.4% during the second quarter. Dimensional Fund Advisors LP now owns 2,205,712 shares of the biopharmaceutical company’s stock worth $74,795,000 after purchasing an additional 152,029 shares during the last quarter. Hedge funds and other institutional investors own 88.44% of the company’s stock.
Several research firms have weighed in on EBS. Zacks Investment Research cut Emergent Biosolutions from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 11th. Wells Fargo & Co reiterated an “outperform” rating and issued a $43.00 price target (up from $41.00) on shares of Emergent Biosolutions in a research note on Saturday, September 30th.
In related news, Director Ronald Richard sold 23,681 shares of the stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $45.02, for a total value of $1,066,118.62. Following the completion of the sale, the director now directly owns 47,091 shares in the company, valued at $2,120,036.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Daniel Abdun-Nabi sold 31,508 shares of the stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $42.77, for a total value of $1,347,597.16. Following the completion of the sale, the chief executive officer now owns 215,642 shares of the company’s stock, valued at $9,223,008.34. The disclosure for this sale can be found here. Insiders sold a total of 206,329 shares of company stock valued at $8,892,362 over the last quarter. 16.50% of the stock is owned by corporate insiders.
Emergent Biosolutions Inc (NYSE:EBS) opened at $47.54 on Tuesday. Emergent Biosolutions Inc has a 12 month low of $27.94 and a 12 month high of $49.25. The company has a market capitalization of $1,960.00, a price-to-earnings ratio of 29.71, a PEG ratio of 0.99 and a beta of 1.29. The company has a quick ratio of 6.46, a current ratio of 7.37 and a debt-to-equity ratio of 0.38.
Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 EPS for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.32. Emergent Biosolutions had a return on equity of 15.20% and a net margin of 15.60%. The company had revenue of $149.43 million during the quarter, compared to analysts’ expectations of $124.55 million. During the same period in the prior year, the company earned $0.56 EPS. Emergent Biosolutions’s revenue was up 4.6% compared to the same quarter last year. sell-side analysts predict that Emergent Biosolutions Inc will post 1.66 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Emergent Biosolutions Inc (EBS) Holdings Trimmed by California State Teachers Retirement System” was first published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.truebluetribune.com/2018/01/16/emergent-biosolutions-inc-ebs-holdings-trimmed-by-california-state-teachers-retirement-system.html.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.